Democratic Republic of Congo’s Ebola epidemic surpasses 6,000 cases

By the Editorial Team · Tuesday, September 1, 2026

The Democratic Republic of Congo has reported over 6,000 confirmed cases and nearly 3,000 deaths from the Bundibugyo strain of Ebola in its deadliest outbreak to date. The outbreak’s containment is complicated by the lack of a specific vaccine, ongoing regional instability, and challenges in early detection, prompting clinical trials for new treatments and calls for increased international support.

The Democratic Republic of Congo (DRC) has surpassed 6,000 confirmed cases of Ebola in its current outbreak, with nearly 3,000 fatalities, marking the country’s deadliest Ebola epidemic to date. According to the latest figures released by Congolese health authorities, 6,041 cases have been confirmed since the outbreak was declared in mid-May, with 2,911 deaths and 1,366 recoveries. Currently, around 619 patients remain in isolation or are receiving treatment.

This outbreak involves the Bundibugyo strain of the Ebola virus, which experts say is challenging to contain partly because there is no specific vaccine or approved treatment for this variant. The World Health Organization (WHO) announced the epidemic in May, although experts suggest that infections may have begun as early as February, going initially undetected. Since then, the virus has spread across six provinces in the northeastern and eastern parts of the DRC, including the Ituri province, which was first affected.

The scope of the outbreak has been exacerbated by the region’s ongoing instability. Armed groups operating in the mineral-rich eastern provinces have hindered the response efforts, while mistrust of the authorities within affected communities has posed additional challenges for health workers. The Congolese health authorities noted that the Bundibugyo variant often presents with mild symptoms initially, complicating early detection and containment efforts.

In response, clinical trials for two antiviral treatments have been underway since early July. Additionally, a clinical trial involving the Ervebo vaccine, which is approved for the Zaire strain of Ebola, began recently, although its effectiveness against the Bundibugyo strain is still under evaluation. The Africa Centres for Disease Control and Prevention has indicated that suspicions of a possible mutation in the Bundibugyo strain have not been confirmed.

Despite these efforts, experts believe that the number of actual cases may be higher than reported due to limitations in surveillance and the challenging operating environment in the affected areas. The ongoing outbreak remains a significant public health crisis in the DRC, raising concerns about the need for enhanced international support and improved access to affected communities to control the spread of the disease.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.